ライフサイエンスコーパス: emesis

1 ects on PDE4B (anti-inflammatory) and PDE4D (emesis).

2 g nonrespiratory responses (e.g. coughing or emesis).

3 itors cannot be used in humans due to severe emesis.

4 ethasone for prevention of acute and delayed emesis.

5 MK-869 plus dexamethasone in reducing acute emesis.

6 methasone provided the best control of acute emesis.

7 d 10(10) CFU experienced watery diarrhea and emesis.

8 sma drug levels without associated nausea or emesis.

9 and another experienced a single episode of emesis.

10 catharsis and emesis and from vomitus during emesis.

11 xamethasone improves the prevention of acute emesis.

12 bserved prevention rate or delay the time to emesis.

13 the two-dose regimen in those patients with emesis.

14 nts receiving the same prophylaxis for acute emesis.

15 efficacy and toxicity in preventing delayed emesis.

16 been hampered by their major side effect of emesis.

17 pus enhances memory but appears not to cause emesis.

18 f nausea, which is not as well controlled as emesis.

19 e salivation, or physiological correlates of emesis.

20 5 mg/kg, no injections completely eliminated emesis.

21 rease) in correlation with cisplatin-induced emesis.

22 s alternative models of chemotherapy-induced emesis.

23 s physiological roles in control of pain and emesis.

24 inal pain/nausea/dehydration and grade 4 AST/emesis.

25 postoperative pain and reduced postoperative emesis.

26 is recommended for the prevention of delayed emesis.

27 ethasone to protect one patient from delayed emesis.

28 after chemotherapy for prevention of delayed emesis.

29 stance P antagonist for chemotherapy-induced emesis.

30 ties included flu-like symptoms, nausea, and emesis.

31 %), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms.

32 4 toxicities included diarrhea (38%), nausea/emesis (19%), fatigue (16%), dehydration (16%), and derm

33 4%), grade 3 fatigue (14.3%), grade 3 nausea/emesis (22%), grade 3 diarrhea (10%), and grade 3 mucosi

34 toclopramide [P = .023]) but not episodes of emesis (5.0 [SD, 3.1] vs 3.3 [SD, 3], respectively [P =

35 R, 2.37; 95% CI, 1.09 to 5.15; P = .026) and emesis (78% v 65%; OR, 1.99; 95% CI, 1.25 to 3.18; P = .

36 c modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active s

37 dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk

38 ethasone for prevention of acute and delayed emesis after high-dose cisplatin.

39 ceptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin.

40 nd diarrhea were more common with erlotinib; emesis, alopecia, peripheral neuropathy, and fatigue wer

41 Operating time, postoperative emesis, analgesia requirements, time to full feeding, le

42 l tolerated; the principal side effects were emesis and a transient decrease in blood pressure.

43 ts that are relevant to clinical efficacy in emesis and depression.

44 ir, or saliva before and after catharsis and emesis and from vomitus during emesis.

45 The main risk factors are postoperative emesis and intraoperative extensive photocoagulation.

46 onergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

47 to 4 hours of food ingestion with repetitive emesis and lethargy.

48 ebo in controlling cisplatin-induced delayed emesis and may provide additive benefit in acute emesis

49 of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin.

50 is and may provide additive benefit in acute emesis and nausea control when combined with a 5-hydroxy

51 ects of apomorphine treatment include severe emesis and nausea, and ulceration and pain at the inject

52 ated with higher complete response rates (no emesis and no rescue medications) compared with palonose

53 point (complete response) was defined as no emesis and no rescue therapy within 120 hours of melphal

54 primary end point was complete response (no emesis and no rescue therapy) on days 1 to 5 postcisplat

55 e primary end point; a complete response (no emesis and no use of rescue medication) was a secondary

56 N, and PBN are associated with activation of emesis and perhaps nausea.

57 produced vomiting only, GR73632 caused both emesis and scratching behavior dose-dependently in shrew

58 of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-res

59 expiratory muscles during behaviors such as emesis and some postural adjustments can be elicited thr

60 well as incidence and severity of nausea and emesis and use of antiemetic rescue medication.

61 ghty-eight percent had hematochezia, 63% had emesis, and 33% had intermittent diarrhea before surgery

62 virus administration were flu-like symptoms, emesis, and abdominal pain.

63 Nausea, emesis, and anorexia are common features of these disord

64 disorders are often associated with nausea, emesis, and anorexia.

65 hat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour, th

66 , fever, headache, abdominal pain, diarrhea, emesis, and fatigue) with symptoms of other more common

67 Patients had nausea, emesis, and obtundation.

68 ased the incidence of postreinfusion nausea, emesis, and oxygen desaturation in comparison to unselec

69 ipheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.

70 not significantly improve control of delayed emesis as compared with dexamethasone monotherapy (ARR,

71 (LES) is critical for normal swallowing and emesis, as well as for the prevention of gastroesophagea

72 sted as gastrointestinal stasis, nausea, and emesis associated with illness.

73 hibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concent

74 eduction in emetic side effects (ferret, 20% emesis at 30 mg/kg, po).

75 Although SSP-SAP injection reduced emesis at GR73632 doses of 2.5 and 5 mg/kg, no injection

76 nism-related side effects such as nausea and emesis at high doses.

77 f side effects such as ataxia, sedation, and emesis at this dose.

78 ve for preventing acute chemotherapy-induced emesis but the benefits of continuing administration of

79 ommodate food during ingestion and preceding emesis, but has quite different functions from the antru

80 marketed for prevention of vagally-mediated emesis caused by cancer chemotherapeutic agents.

81 ninergic system is not well-characterized in emesis-competent species.

82 s, chest and abdominal pain, nausea, bilious emesis, cough, and shortness of breath.

83 indicates that acupuncture is effective for emesis developing after surgery or chemotherapy in adult

84 ng the same antiemetic prophylaxis for acute emesis, dexamethasone was not superior to aprepitant but

85 adverse gastrointestinal symptoms, including emesis, diarrhea, abdominal cramping, and gastrointestin

86 mon toxicities included pain, fever, nausea, emesis, diarrhea, urticaria, mild elevation of hepatic t

87 udy was the proportion of patients free from emesis during the study period.

88 of this combination included fever, nausea, emesis, electrolyte imbalance, and fluid retention that

89 percentage of patients who developed delayed emesis (emesis on the second to fifth days after cisplat

90 There were significantly fewer number of emesis episodes and doses of analgesia given in the lapa

91 The number of emesis episodes occurring during the 5 days was lower fo

92 Complete control of emesis (expressed as the percentage of patients who had

93 Nausea, emesis, fatigue, dehydration, and hyponatremia also were

94 assessed by modified Functional Living Index-Emesis (FLIE) questionnaire on days -1 and 6.

95 The proportion of nausea- and emesis-free patients at 24 and 48 hours were also approx

96 Saliva before and after emesis grew low quantities of H pylori in 3 (18.8%) and

97 dies on the etiology of chemotherapy-related emesis have implicated brainstem nuclei and the neurotra

98 xicities included fatigue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and

99 r toxicities have been documented, including emesis, hypersensitivity reactions, cardiovascular event

100 oncerned with neuro-otology, pharmacology of emesis, imaging, cochlear prostheses and aspects of vert

101 hasone 20 mg given only once prevented acute emesis in 76% of patients who received cisplatin > or =

102 Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophyla

103 nd oral dexamethasone 20 mg to prevent acute emesis in cancer patients receiving initial cisplatin at

104 central opioids may induce APCs and prevent emesis in conscious dogs.

105 t, at 5 mg/kg it failed to cause significant emesis in either phase, while its 20 mg/kg dose induced

106 d period, the proportion of patients without emesis in groups I, II, III, and IV was 29%, 63%, 51%, a

107 , 80%, 46%, and 43% of patients were without emesis in groups I, II, III, and IV, respectively (P <.0

108 Although compound 2 produces emesis in humans when given as a single dose, its exempl

109 ent visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic c

110 superior to aprepitant in preventing delayed emesis in patients receiving the same prophylaxis for ac

111 Only SEC1 induced emesis in the monkey feeding assay.

112 Drug-related grade 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two p

113 nded for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines

114 les in depression, anxiety, substance abuse, emesis, inflammatory pain, spinal nociception, gastroint

115 es of agents affecting receptors involved in emesis is necessary to effectively treat PONV.

116 tion of acute childhood poisonings for which emesis is not contraindicated.

117 ggest that acupuncture may reduce nausea and emesis, it is unclear whether such benefit comes from th

118 hemotherapy poses considerable challenges to emesis management.

119 -mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocamp

120 ogues were found to be nonemetic in a canine emesis model at intravenous doses of up to 3 mg/kg.

121 st shrew appears to be a sensitive and rapid emesis model for both phases of CIV, and both emetic pha

122 s in humans and least shrews, a small animal emesis model which also vomits in response to substance

123 n to further establish Cryptotis parva as an emesis model, by sequencing and characterizing SP mRNA,

124 e evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.

125 se of general anxiety (n = 5), nausea and/or emesis (n = 2), or asymptomatic occlusion of an external

126 onhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia.

127 ary efficacy end point was total control (no emesis, no nausea, and no use of antiemetic rescue medic

128 platin, we evaluated the prevention of acute emesis (occurring within 24 hours) and delayed emesis (o

129 d Relevance: For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines,

130 ge of patients who developed delayed emesis (emesis on the second to fifth days after cisplatin).

131 esis (occurring within 24 hours) and delayed emesis (on days 2 to 5) after a single dose of cisplatin

132 The presence or absence of posttussive emesis or inspiratory whoop modestly change the likeliho

133 Additional medication was available to treat emesis or nausea at any time.

134 f patients achieving a complete response (no emesis or use of rescue medication) in the delayed phase

135 achieving a complete response (defined as no emesis or use of rescue medication) in the delayed phase

136 ng was not essential for T cell stimulation, emesis, or lethality although in general the mutants wer

137 models of central nervous system behaviors, emesis, or nausea.

138 no nausea, score of Functional Living Index-Emesis; P < .24).

139 nt clinical features of FPIES are repetitive emesis, pallor, and lethargy; chronic FPIES can lead to

140 The median nausea score in the delayed-emesis phase was significantly lower in group 1 than in

141 In the delayed-emesis phase, 82 percent of the patients in group 1, 78

142 In the acute-emesis phase, 93 percent of the patients in groups 1 and

143 e photocoagulation (OR, 4.94; P < .001), and emesis postoperatively (OR, 24.39; P < .001).

144 rs of delayed suprachoroidal hemorrhage were emesis postoperatively (P < .001) and extensive intraope

145 There was no observed difference in emesis prevention between the one-dose (76%) and two-dos

146 vention of acute (0 to 24 hours) and delayed emesis (primary efficacy parameter; days 2 to 5) after c

147 ation of peripheral NK1 receptors can affect emesis produced by GR73632.

148 As yet, no study has confirmed that emesis produced by SP or a selective NK1 receptor agonis

149 ticosteroids vs metoclopramide was reported (emesis reduction, 40.9% vs 16.5% at day 2; 71.6% vs 51.2

150 l grey, trigeminal nuclei, dorsal raphe, and emesis-related brainstem nuclei including the area postr

151 beyond 24 hours after chemotherapy (delayed emesis) remain unclear.

152 C. parva as a model organism, especially for emesis research.

153 Presence of posttussive emesis (summary likelihood ratio [LR], 1.8; 95% confiden

154 y LR, 0.52; 95% CI, 0.27-1.0) or posttussive emesis (summary LR, 0.58; 95% CI, 0.44-0.77) reduced the

155 cupuncture was more effective in controlling emesis than minimal needling or antiemetic pharmacothera

156 minimal needling group had fewer episodes of emesis than the antiemetic pharmacotherapy alone group (

157 ectroacupuncture group had fewer episodes of emesis than the minimal needling group (P<.001), whereas

158 component in neurokinin NK-receptor mediated emesis, the authors undertook this study to examine the

159 of overlapping and interrelated problems of emesis, vertigo and migraine which promises an early sol

160 P (SP) is thought to play a cardinal role in emesis via the activation of central tachykinin NK1 rece

161 The median time to the onset of emesis was 19 hours for the one-dose regimen and 17 hour

162 The rate of complete control of emesis was 61.2% in the granisetron group and 67.1% in t

163 Emesis was associated with 10.5 g SNAC.

164 sed as the percentage of patients who had no emesis) was as follows: day 1, 85.7% (group 1) and 66.7%

165 kg dose of cisplatin produced both phases of emesis with corresponding peak mean frequencies occurrin

166 e acute [< or = 24 hours after chemotherapy] emesis without antiemetic prophylaxis); level 2 (10% to